Literature DB >> 8488715

Dramatic reduction of meningococcal meningitis among military recruits in Italy after introduction of specific vaccination.

R Biselli1, A Fattorossi, P M Matricardi, R Nisini, T Stroffolini, R D'Amelio.   

Abstract

Meningococcal meningitis is still a serious infectious disease with a mortality rate that can be as high as 10% even in developed countries. Military recruits are generally a high-risk group for meningococcal disease, with a reported incidence of four to ten times greater than that of the general population. In Italy the results of the National Meningitis Surveillance Programme showed a high attack rate of the disease among recruits in 1985 as well as in 1986, with 92 and 95% of the cases, respectively, caused by serogroup C and thus preventable. These findings led to the authorities' decision to make vaccination against meningococcal disease mandatory for recruits starting from January 1987. After almost 5 years from the introduction of meningococcal vaccination, we here sum up the epidemiological and immunological effects of the vaccination. From the epidemiological point of view we have observed a dramatic reduction of the prevalence of the disease. In 1987, the year in which we had 150,000 unvaccinated and 150,000 vaccinated recruits, the protective efficacy was 91.2%. From the immunological point of view, vaccination is highly effective, as seroconversion against polysaccharide (PS) A and C is 84 and 91%, respectively. The spectrotypic analysis of the sera before and after vaccination shows that the type of response is mainly oligoclonal, like the majority of the responses to PSs, and the antibodies induced by a sole PS are not qualitatively different from the antibodies induced by natural immunization. In addition, the efficacy is not modified by environmental factors like hypoxia, as demonstrated during permanence at 16,174 feet for 20 days.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8488715     DOI: 10.1016/0264-410x(93)90236-q

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

Review 1.  Vaccination against meningococcus in complement-deficient individuals.

Authors:  B P Morgan; A Orren
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

2.  Dramatic decline of serogroup C meningococcal disease incidence in Catalonia (Spain) 24 months after a mass vaccination programme of children and young people.

Authors:  L Salleras; A Domínguez; G Prats; I Parron; P Muñoz
Journal:  J Epidemiol Community Health       Date:  2001-04       Impact factor: 3.710

3.  Immunogenicity of meningococcal polysaccharide ACWY vaccine in primary immunized or revaccinated adults.

Authors:  C Ferlito; R Biselli; M S Cattaruzza; R Teloni; S Mariotti; E Tomao; G Salerno; M S Peragallo; P Lulli; S Caporuscio; A Autore; G Bizzarro; V Germano; M I Biondo; A Picchianti Diamanti; S Salemi; R Nisini; R D'Amelio
Journal:  Clin Exp Immunol       Date:  2018-09-20       Impact factor: 4.330

Review 4.  Meningococcal glycoconjugate vaccines.

Authors:  Roberto Gasparini; Donatella Panatto
Journal:  Hum Vaccin       Date:  2011-02-01

Review 5.  Meningococcal vaccines. Current status and future possibilities.

Authors:  H Peltola
Journal:  Drugs       Date:  1998-03       Impact factor: 9.546

Review 6.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

7.  Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England.

Authors:  Nick Andrews; Ray Borrow; Elizabeth Miller
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

Review 8.  Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field.

Authors:  Prasad S Kulkarni; Julia L Hurwitz; Eric A F Simões; Pedro A Piedra
Journal:  Viral Immunol       Date:  2018-01-16       Impact factor: 2.257

9.  Meningococcal conjugate vaccines: optimizing global impact.

Authors:  Andrew Terranella; Amanda Cohn; Thomas Clark
Journal:  Infect Drug Resist       Date:  2011-09-21       Impact factor: 4.003

Review 10.  Global practices of meningococcal vaccine use and impact on invasive disease.

Authors:  Asad Ali; Rabab Zehra Jafri; Nancy Messonnier; Carol Tevi-Benissan; David Durrheim; Juhani Eskola; Florence Fermon; Keith P Klugman; Mary Ramsay; Samba Sow; Shao Zhujun; Zulfiqar Bhutta; Jon Abramson
Journal:  Pathog Glob Health       Date:  2014-01       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.